Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias-Reference-Cited by-同舟云学术

Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias

Published:2023-07-21 Issue:1 Volume:28 Page:
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zou Jing-Ying¹,Huang Si-Man²³,Zhoub Hai-Xia²³,Xu Ming-Zhu²³,Sun Ai-Ning²³,Wu De-Pei²³,Xue Sheng-Li²³,Zhang Tong-Tong²³

Affiliation:

1. Suzhou Vocational Health College, Suzhou, People’s Republic of China

2. Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China

3. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China

Funder

Jiangsu Overseas Visiting Scholar Program for University Prominent Young & Middle-aged Teachers and Presidents

National Natural Science Foundation of China

Translational Research Grant of NCRCH

Social Development Project of the Science and Technology Department of Jiangsu

Jiangsu Province “333” project

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2023.2237790